Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib rollover extension study for BRAF V600 mutation-positive malignancies
NL-OMON40515Phase 4Active, not recruiting
- Sponsor
- Roche
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vemurafenib in Nonhematologic neoplasms and cancer, sponsored by Roche. Primary endpoints: Incidence, nature, and intensity of adverse events and serious adverse events and No protocol-specific efficacy outcome measures. Started Jul 2013; status: active, not recruiting.
02
Drugs
vemurafenib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on NL-OMON40515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40515.